Benitec Biopharma Stock (NASDAQ:BNTC)
Previous Close
$13.98
52W Range
$8.20 - $17.15
50D Avg
$12.54
200D Avg
$12.70
Market Cap
$363.57M
Avg Vol (3M)
$111.96K
Beta
0.43
Div Yield
-
BNTC Company Profile
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.